Poster 18

Efficacy and Safety of Ruxolitinib Cream Among Children With Atopic Dermatitis Aged 2 to 6 Years and 7 to 11 Years: Results From a Phase 3 Double-Blind, Vehicle-Controlled Study

Authors: Weily Soong, MD, Andrea Zaenglein, MD, Megha M. Tollefson, MD, Eric L. Simpson, MD, MCR, Alim R. Devani, MD, Joel C. Joyce, MD, Douglass Forsha, MD, Joel Schlessinger, MD, Howard Kallender, PhD, Brett Angel, MD, Qian Li, PhD, Amy S. Paller, MD

<PREVIOUS POSTER | NEXT POSTER>

Poster 18